A first-in-human study by Mass General Brigham Cancer Institute investigators found that a chimeric antigen receptor (CAR) T-cell therapy called TriPRIL reduced or eliminated signs of cancer in 12 of 15 patients with relapsed or refractory multiple myeloma. TriPRIL - short for trimeric APRIL (a proliferation-inducing ligand) - recognizes two proteins on myeloma cells instead of just one. Researchers published their findings in The Lancet.
Multiple myeloma is a cancer of plasma cells, which are immune cells that make antibodies. To create CAR T-cell therapy, scientists modify a patient's T cells so they can find and attack myeloma cells. Existing CAR T-cell therapies recognize B-cell maturation antigen (BCMA) on myeloma cells. TriPRIL was engineered by Mass General Brigham researchers to make the CAR-T cells recognize both BCMA and a second protein, transmembrane activator and CAML interactor (TACI). Because the treatment is based on human proteins, the researchers believe it may be less likely to lead to anti-drug antibodies that can reduce the long-term persistence and effects of other CAR-T cells.
"BCMA-targeted CAR T-cell therapy has transformed multiple myeloma treatment, but most patients eventually relapse," said co-senior author Marcela V. Maus, MD, PhD, director of the Mass General Brigham Cancer Institute's Cellular Immunotherapy Program. "TriPRIL adds TACI as a second target, allowing it to find and attack myeloma cells, even if they stop expressing BCMA."
The phase 1 TriPRIL trial treated 15 patients at the Mass General Brigham Cancer Institute whose multiple myeloma had come back despite many treatments. Nine patients had previously received BCMA-directed CAR T-cell therapy but saw their cancer progress. Twelve of the fifteen patients (80%) responded, meaning cancer signs fell by at least half. In eight (53%), blood, urine and bone marrow tests found no signs of active myeloma.
TriPRIL cells remained detectable in some patients' blood beyond six months after treatment. The treatment was also relatively safe, with no severe cases of cytokine release syndrome or neurotoxicity.
Seeing this new treatment work in patients whose cancer had returned after treatment targeting BCMA stood out.
Marcela V. Maus, MD, PhD, Director, Cellular Immunotherapy Program, Mass General Brigham Cancer Institute
It was also encouraging that the patients we tested showed no immune reaction against TriPRIL.
Because the study included only 15 patients and followed them for a relatively short time, researchers need larger, longer studies to determine how long the benefits last and identify less common side effects. They are planning a phase 2 trial with more patients and longer follow-up.
Source:
Journal reference:
Puliafito, B. R., et al. (2026) Natural ligand-based CAR T-cell therapy targeting BCMA and TACI for relapsed or refractory multiple myeloma (TriPRIL): A non-randomised, phase 1, first-in-human trial. The Lancet. DOI:10.1016/s0140-6736(26)01806-4. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01806-4/abstract.